Last checked at 4 Oct 2023 12:34
Â
Destiny Pharma plc
Â
("Destiny Pharma" or the "Company")
Â
Director/PDMR Shareholding
Â
Brighton, United Kingdom - 4 October 2023 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and treat life threatening infections, announces that it was notified on 4 October 2023 that on 29 September 2023, Dr William Love, Chief Scientific Officer of the Company, transferred 2,300,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to his wife, a PCA, by way of gift for nil consideration.
Â
Following the transfer, Dr William Love's beneficial interest in the Company remains unchanged at 6,509,500 Ordinary Shares, representing 6.83 per cent. of the total issued share capital.
Â
Â
For further information, please contact:
Â
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com
Â
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Â
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Â
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward
+44 (0) 20 7250 1446
Destiny@powerscourt-group.com
Â
About Destiny Pharma
Â
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
Â
Â
For further information on the Company, please visit www.destinypharma.com
Â
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.
Â
Â
Â
Â
Â
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Â
1.               | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Dr William Love |
2.               | Reason for the Notification | |
a) | Position/status | Chief Scientific Officer |
b) | Initial notification/Amendment | Initial notification |
3.    | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Destiny Pharma plc |
b) | LEI | 213800O9WH9Z38EHAC95 |
4.    | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1 pence each |
Identification code | DESTÂ Â Â Â GB00BDHSP575 | |
b) | Nature of the transaction | Transfer of Ordinary Shares, by way of gift, to Carol Love, a Person Closely Associated with him, for nil consideration. |
c) | Price(s) and volume(s) | Â 0 (gift) Â 2,300,000 Ordinary Shares |
d) | Aggregated information: Aggregated volume Price |  See 4c) above  |
e) | Date of the transaction | 29 September 2023 |
f) | Place of the transaction | Off-Market |
Â
Â